Identifier
Created
Classification
Origin
09CANBERRA686
2009-07-27 22:14:00
UNCLASSIFIED//FOR OFFICIAL USE ONLY
Embassy Canberra
Cable title:
GOA REJECTS PROPOSAL TO MANUFACTURE GENERIC DRUGS
how-toVZCZCXRO7607 RR RUEHPT DE RUEHBY #0686 2082214 ZNR UUUUU ZZH R 272214Z JUL 09 FM AMEMBASSY CANBERRA TO RUEHC/SECSTATE WASHDC 1832 INFO RUEHBN/AMCONSUL MELBOURNE 6550 RUEHPT/AMCONSUL PERTH 4815 RUEHDN/AMCONSUL SYDNEY 4790
UNCLAS CANBERRA 000686
SENSITIVE
SIPDIS
WHITE HOUSE FOR USTR
DEPARTMENT FOR EAP/ANP, EEB/TPP/IPE
E.O. 12958: N/A
TAGS: ETRD TBIO AS
SUBJECT: GOA REJECTS PROPOSAL TO MANUFACTURE GENERIC DRUGS
FOR EXPORT
UNCLAS CANBERRA 000686
SENSITIVE
SIPDIS
WHITE HOUSE FOR USTR
DEPARTMENT FOR EAP/ANP, EEB/TPP/IPE
E.O. 12958: N/A
TAGS: ETRD TBIO AS
SUBJECT: GOA REJECTS PROPOSAL TO MANUFACTURE GENERIC DRUGS
FOR EXPORT
1. (U) SUMMARY: The GOA rejected a proposal by generics
companies to manufacture generic drugs in Australia for
export. Pharmaceutical industry groups welcomed the decision
while generic manufacturers were disappointed. The GOA based
the decision mainly on its declared intent to adhere by
Australia's international commitments. End Summary.
2. (SBU) On July 25 Econoff met with Ian Chalmers, Chief
Executive of Medicines Australia, an industry group
representing pharmaceuticals in Australia. Chalmers
confirmed that the GOA rejected a proposal that would have
allowed the manufacture of generic drugs in Australia for
export. The proposal was put forth by global pharmaceutical
Hospira and was backed by the Generic Medicines Industry
Association of Australia (GMiA).
3. (SBU) Chalmers provided a copy of a letter dated July 22
from Minister for Innovation, Industry, Science and Research
Kim Carr to Medicines Australia, in which the GOA conveyed
its position on the manufacturing of generics for export.
Explaining that the issue had been given "careful and
thorough consideration by relevant departments and agencies,"
Minister Carr concluded that the GOA cannot support the
proposal "in light of Australia's international commitments
on intellectual property and trade."
4. (U) GMiA Chief Executive Kate Lynch released a statement
lamenting the government's decision and warning that it will
have a "detrimental impact" on the development of the generic
medicines industry in Australia. She added that as a result
of the decision Australian generic medicine manufacturers
will miss a share of USD 150 billion export market over the
next six years.
5. (SBU) COMMENT: While rejecting the proposal seems like
straightforward compliance with the Australia-US Free Trade
Agreement (AUSFTA),some experts have argued that the GOA
could have expanded its interpretation of the FTA in order to
allow the manufacture of generics for export. Given that
AUSFTA negotiations on intellectual property were
particularly difficult, the GOA may have preferred to tread
lightly on this issue.
SENSITIVE
SIPDIS
WHITE HOUSE FOR USTR
DEPARTMENT FOR EAP/ANP, EEB/TPP/IPE
E.O. 12958: N/A
TAGS: ETRD TBIO AS
SUBJECT: GOA REJECTS PROPOSAL TO MANUFACTURE GENERIC DRUGS
FOR EXPORT
1. (U) SUMMARY: The GOA rejected a proposal by generics
companies to manufacture generic drugs in Australia for
export. Pharmaceutical industry groups welcomed the decision
while generic manufacturers were disappointed. The GOA based
the decision mainly on its declared intent to adhere by
Australia's international commitments. End Summary.
2. (SBU) On July 25 Econoff met with Ian Chalmers, Chief
Executive of Medicines Australia, an industry group
representing pharmaceuticals in Australia. Chalmers
confirmed that the GOA rejected a proposal that would have
allowed the manufacture of generic drugs in Australia for
export. The proposal was put forth by global pharmaceutical
Hospira and was backed by the Generic Medicines Industry
Association of Australia (GMiA).
3. (SBU) Chalmers provided a copy of a letter dated July 22
from Minister for Innovation, Industry, Science and Research
Kim Carr to Medicines Australia, in which the GOA conveyed
its position on the manufacturing of generics for export.
Explaining that the issue had been given "careful and
thorough consideration by relevant departments and agencies,"
Minister Carr concluded that the GOA cannot support the
proposal "in light of Australia's international commitments
on intellectual property and trade."
4. (U) GMiA Chief Executive Kate Lynch released a statement
lamenting the government's decision and warning that it will
have a "detrimental impact" on the development of the generic
medicines industry in Australia. She added that as a result
of the decision Australian generic medicine manufacturers
will miss a share of USD 150 billion export market over the
next six years.
5. (SBU) COMMENT: While rejecting the proposal seems like
straightforward compliance with the Australia-US Free Trade
Agreement (AUSFTA),some experts have argued that the GOA
could have expanded its interpretation of the FTA in order to
allow the manufacture of generics for export. Given that
AUSFTA negotiations on intellectual property were
particularly difficult, the GOA may have preferred to tread
lightly on this issue.